Nasdaq
$78.31▲ 1.89%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.28BShares out 54.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 9.18After-hours26.09.19 05:364Ownership#●●●
Dianthus Therapeutics, Inc. /DE/
Insider Edward Carr of Dianthus Therapeutics, Inc. filed a Form 4 on September 18, 2026, reporting changes in beneficial ownership of securities as of September 17, 2026. This filing serves as an official record of the insider's equity transaction.…more
$78.31+1.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18After-hours26.09.19 05:02S-3ASROffering
Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics has entered into an 'At-the-Market' (ATM) sales agreement with TD Securities (TD Cowen) to issue and sell up to $500 million of its common stock from time to time. Through this S-3ASR filing, the company has registered a shelf offering for various securities, including common stock, preferred stock, debt securities, warrants, and units, to provide flexibility for future capital raising.…more
$78.31+1.89%vs prev closeView filingShare - 9.17After-hours26.09.18 05:28144Ownership
Dianthus Therapeutics, Inc. /DE/
Edward Carr, an insider at Dianthus Therapeutics, has filed a Form 144 to report a proposed sale of company shares. This is a standard disclosure regarding an insider's plan to dispose of their holdings.…more
$78.31+1.89%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 21:45#●●●
Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma…more
Dianthus Therapeutics has been recognized as one of the 2026 Best Workplaces in BioPharma by Fortune and Great Place To Work. While this highlights the company's workplace culture and employee engagement, it does not provide direct financial or operational catalysts for the stock.…more
$78.31+1.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 06:00
●●●●●●●● ●●●●● ●●●●●●
Dianthus Therapeutics has granted stock options for 106,000 shares to six newly hired employees as an employment inducement. This is a standard compensation practice for talent acquisition and has no significant impact on the company's financial outlook.…more
$78.31+1.89%vs prev close - 9.29Pre-market26.09.29 21:00
●●●●●●●● ●●●●● ●●●●●●
Dianthus Therapeutics announced plans to present clinical data for its investigational drug, claseprubart, at the 2026 AANEM Annual Meeting. The presentations will cover interim results from ongoing Phase 2 and Phase 3 trials for autoimmune neuromuscular disorders.…more
$78.31+1.89%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report